Experimental drug used to treat recurrent ovarian cancer shows promising results

Yale researchers have reported promising preliminary results of a Phase Ib/IIa study in women with recurrent ovarian cancer using phenoxodiol, an experimental anti-cancer drug that could kill cancer cells and increase effectiveness of standard chemotherapy.

The data were presented by David O'Malley, M.D., instructor, Department of Obstetrics, Gynecology & Reproductive Sciences, at the 35th Annual Meeting of the Society of Gynecologic Oncologists in San Diego, California on February 8. The researchers found no toxicity, 25 percent response and synergy with chemotherapy. The main purpose of the study was to determine the dose of phenoxodiol to be used in combination with other anti-cancer drugs.

While phenoxodiol has the ability to stop ovarian cancer growth in animals in its own right, Yale researchers and the drug's developer, Marshall Edwards, Inc., are developing the drug in late-stage ovarian cancer as a chemo-sensitizer, restoring the sensitivity of the cancer cells to standard chemotherapeutic drugs.

"Patients received phenoxodiol twice a week, which is how we believe it will be used in combinational therapy," said principal investigator Thomas Rutherford, M.D., associate professor of gynecology, Department of Obstetrics, Gynecology & Reproductive Sciences. "We did expect to see a major anti-tumor effect when used at this dose, with an apparent 25 percent stability rate in unresponsive cancers. These results gave us confidence in the potential use of phenoxodiol for the treatment of ovarian cancer. We are highly encouraged by the outcome."

The data reflected outcomes from the first 20 of 40 patients enrolled in the study with late-stage ovarian cancer that had become unresponsive to standard chemotherapy. Of the 20 patients who started the course of treatment, 13 were able to finish a three-month program without disease progression. Five of these patients were evaluated to have disease stabilization; all these

Contact: Karen N. Peart
Yale University

Page: 1 2

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental treatment yields new hope for children battling cerebral palsy
4. Experimental drugs show promise in halting brain tumors
5. Experimental drugs reduce neuron death in rats following insulin shock
6. Experimental pill found to improve symptoms in patients with non-small-cell lung cancer
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. First head-to-head study to compare lidoderm patch and Celebrex in treating pain

Post Your Comments:

(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... ... many businesses, including dental offices for non-emergency work. In conjunction with the American ... guidelines for Connecticut dental practices in mid-May. , Due to safety concerns, ...
(Date:7/1/2020)... Fla. (PRWEB) , ... July 01, 2020 , ... ... LLC specializing in the clinical development of psychedelics and analogues, announces its core ... combined experience in natural product drug discovery, novel formulations, and as distinguished researchers ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Pool ... revision and redesignation of the ANSI/APSP/ICC-7 2013 American National Standard for Suction Entrapment ... is seeking member participation on the PHTA-7 Standard Writing Committee (SWC) for Suction ...
(Date:6/28/2020)... ... 26, 2020 , ... Recovery from drug and alcohol addiction ... center, proudly announces that it has reopened to serve new clients with a ... world affected by Covid-19. , When social-distancing guidelines changed the way residential facilities ...
(Date:6/28/2020)... (PRWEB) , ... June 27, 2020 , ... ... Connect Classroom, the first online, full-day educational conference in the organization’s history. The ... for facioscapulohumeral muscular dystrophy (FSHD), which was cancelled this year due to COVID-19. ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... (PRWEB) , ... July 07, 2020 , ... ... announced its partnership with Psych Hub, the leading comprehensive platform for online education ... Health to offer support resources to Substance Use Disorder (SUD) patients throughout each ...
(Date:7/7/2020)... ... July 07, 2020 , ... ... to Navajo Nation residents, the 33 nonprofits who received the latest ISA ... fourth round of funding, the foundation awarded grants totaling $838,527 to the U.S.-based ...
(Date:7/4/2020)... ... July 03, 2020 , ... ... began to welcome visitors at approved capacities, reactivating the state's economy. The government ... other preventive actions. , The most recent opening was beautiful Hacienda Tres Ríos ...
Breaking Medicine Technology:
Cached News: